Transenterix Inc (TRXC) Given Average Recommendation of “Hold” by Brokerages

Shares of Transenterix Inc (NYSEAMERICAN:TRXC) have been assigned an average recommendation of “Hold” from the six brokerages that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and two have given a buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $3.23.

Several equities research analysts have commented on TRXC shares. Ladenburg Thalmann Financial Services set a $5.00 target price on Transenterix and gave the stock a “buy” rating in a report on Friday, October 20th. Stifel Nicolaus boosted their target price on Transenterix from $3.75 to $4.00 and gave the stock a “buy” rating in a report on Tuesday, October 31st. BTIG Research reissued a “hold” rating on shares of Transenterix in a report on Monday, December 18th. Finally, Zacks Investment Research downgraded Transenterix from a “hold” rating to a “sell” rating in a report on Thursday.

Shares of Transenterix (NYSEAMERICAN:TRXC) opened at $1.99 on Friday. The firm has a market capitalization of $408.45, a price-to-earnings ratio of -3.21 and a beta of 2.02. Transenterix has a 12 month low of $0.45 and a 12 month high of $5.00.

In other Transenterix news, CFO Joseph P. Slattery sold 333,000 shares of the company’s stock in a transaction dated Tuesday, November 14th. The stock was sold at an average price of $2.93, for a total value of $975,690.00. Following the completion of the sale, the chief financial officer now owns 440,974 shares in the company, valued at $1,292,053.82. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Todd Pope sold 600,000 shares of the company’s stock in a transaction dated Wednesday, October 18th. The stock was sold at an average price of $3.68, for a total value of $2,208,000.00. Following the completion of the sale, the insider now owns 462,644 shares of the company’s stock, valued at approximately $1,702,529.92. The disclosure for this sale can be found here. In the last three months, insiders sold 1,462,609 shares of company stock worth $4,666,595.

An institutional investor recently raised its position in Transenterix stock. Ladenburg Thalmann Financial Services Inc. grew its stake in Transenterix Inc (NYSEAMERICAN:TRXC) by 87.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 79,150 shares of the medical instruments supplier’s stock after buying an additional 37,000 shares during the quarter. Ladenburg Thalmann Financial Services Inc. owned approximately 0.05% of Transenterix worth $113,000 as of its most recent SEC filing.

WARNING: “Transenterix Inc (TRXC) Given Average Recommendation of “Hold” by Brokerages” was published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The original version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/13/transenterix-inc-trxc-given-average-recommendation-of-hold-by-brokerages.html.

Transenterix Company Profile

TransEnterix, Inc is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera.

Receive News & Ratings for Transenterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transenterix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply